Published in Eur Heart J on April 01, 2001
Impact of specialist follow-up in outpatients with congestive heart failure. CMAJ (2005) 2.50
Treating the right patient at the right time: access to specialist consultation and non-invasive testing. Can J Cardiol (2006) 1.52
Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis. BMC Health Serv Res (2014) 0.87
Comparison between ATS/ERS age- and gender-adjusted criteria and GOLD criteria for the detection of irreversible airway obstruction in chronic heart failure. Clin Res Cardiol (2012) 0.83
Heart failure guidelines and prescribing in primary care across Europe. BMC Health Serv Res (2005) 0.83
Implantable dual-chamber defibrillator for the selective treatment of spontaneous atrial and ventricular arrhythmias: arrhythmia incidence and device performance. J Interv Card Electrophysiol (2005) 0.81
Dosing variability in prescriptions of acetaminophen to children: comparisons between pediatricians, family physicians and otolaryngologists. BMC Pediatr (2013) 0.77
Stroke prevention in patients with atrial fibrillation: the diagnosis and management of hypertension by specialists. Can J Cardiol (2006) 0.75
Management of patients with heart failure: are internists as good as cardiologists? Eur Heart J (2001) 0.75
A comparison of the early outcome of acute myocardial infarction in women and men. The Third International Study of Infarct Survival Collaborative Group. N Engl J Med (1998) 2.42
PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation (2000) 2.19
Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. Diabetologia (2012) 1.85
Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J (1999) 1.76
ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation (1995) 1.75
Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation (1997) 1.68
Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart. Eur Heart J (2001) 1.66
Successful treatment of mitomycin C-associated hemolytic uremic syndrome by plasmapheresis. Nephron (1989) 1.49
Prediction of 6 months left ventricular dilatation after myocardial infarction in relation to cardiac morbidity and mortality. Application of a new dilatation model to GISSI-3 data. Eur Heart J (2002) 1.48
Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol (2001) 1.47
Aspirin does not interact with ACE inhibitors when both are given early after acute myocardial infarction: results of the GISSI-3 Trial. Heart Dis (2001) 1.45
The consequences of under-use of coronary revascularization; results of a cohort study in Northern Italy. Eur Heart J (2001) 1.41
[The history of the SET-UP study (or how difficult is neutrality in clinical research)]. Ital Heart J Suppl (2000) 1.40
Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting. Catheter Cardiovasc Interv (2005) 1.39
[The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type]. Ital Heart J Suppl (2000) 1.39
Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J (1999) 1.36
Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol (1993) 1.34
Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet (1994) 1.32
Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart (2001) 1.32
Comparison of cimetidine 800 mg once daily and 400 mg twice daily in acute duodenal ulceration. Br Med J (Clin Res Ed) (1984) 1.30
Prognostic significance of heart rate variability in post-myocardial infarction patients in the fibrinolytic era. The GISSI-2 results. Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico. Circulation (1996) 1.22
Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab (2012) 1.19
Heterogeneity of left ventricular remodeling after acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-3 Echo Substudy. Am Heart J (2001) 1.17
Precipitating factors and decision-making processes of short-term worsening heart failure despite "optimal" treatment (from the IN-CHF Registry). Am J Cardiol (2001) 1.16
Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J (2000) 1.06
Genetic analysis of Sardinia: I. data on 12 polymorphisms in 21 linguistic domains. Ann Hum Genet (1996) 1.03
Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J (2000) 1.02
Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes. Heart (2002) 1.02
Clinical and epidemiological characteristics of juvenile myocardial infarction in Italy: the GISSI experience. G Ital Cardiol (1998) 1.01
Epidemiologic variables and outcome of 1972 young patients with acute myocardial infarction. Data from the GISSI-2 database. Investigators of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2). Arch Intern Med (1997) 0.99
Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist. J Cardiovasc Pharmacol (1994) 0.97
Comparison of electrocardiographic criteria for diagnosis of left ventricular hypertrophy in hypertension: the MAVI study. Ital Heart J (2000) 0.95
Cost-effectiveness analysis of early lisinopril use in patients with acute myocardial infarction. Results from GISSI-3 trial. Pharmacoeconomics (1998) 0.95
Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial. J Intern Med (2010) 0.94
Electrocardiographic evolutionary changes and left ventricular remodeling after acute myocardial infarction: results of the GISSI-3 Echo substudy. J Am Coll Cardiol (2000) 0.92
[Atenolol i.v. in the acute phase of AMI: the indications, contraindications and interactions with thrombolytic drugs in the GISSI-2 study. The GISSI-2 Researchers. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico]. G Ital Cardiol (1995) 0.91
A simple electrocardiographic predictor of the outcome of patients with acute myocardial infarction treated with a thrombolytic agent. A Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2)-Derived Analysis. J Am Coll Cardiol (1994) 0.91
Communicating the diagnosis of multiple sclerosis - a qualitative study. Mult Scler (2007) 0.91
Distribution of propafenone and its active metabolite, 5-hydroxypropafenone, in human tissues. Am Heart J (1987) 0.90
Within-patient variability of hormone and cytokine concentrations in heart failure. Pharmacol Res (1998) 0.90
Relevance of heart rate as a prognostic factor in patients with acute myocardial infarction: insights from the GISSI-2 study. Eur Heart J (1998) 0.88
Amiodarone distribution in human tissues after sudden death during Holter recording. Am J Cardiol (1983) 0.87
GISSI-2: mortality plus extensive left-ventricular damage as "end-point". Lancet (1990) 0.87
Comparison of one-year outcome in women versus men with chronic congestive heart failure. Am J Cardiol (2000) 0.87
Aldosterone status associated with insulin resistance in patients with heart failure--data from the ALOFT study. Heart (2009) 0.86
Antiarrhythmic mechanisms of n-3 PUFA and the results of the GISSI-Prevenzione trial. J Membr Biol (2005) 0.85
Flecainide distribution in human tissues. Br J Clin Pharmacol (1987) 0.85
[Standards and guidelines for cardiac rehabilitation. Working Group on Cardiac Rehabilitation of the European Society for Cardiology]. Cardiologia (1999) 0.85
Very early assessment of risk for in-hospital death among 11,483 patients with acute myocardial infarction. GISSI investigators. Am Heart J (1999) 0.84
What does the future hold for BNP in cardiology? Heart (2001) 0.84
Incidental video-capsule diagnosis of small-bowel Taenia saginata in a patient with recurrent hemorrhage due to angiodysplasias. Endoscopy (2006) 0.84
Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). Diabetes Obes Metab (2008) 0.84
Reproducibility of wall motion score and its correlation with left ventricular ejection fraction in patients with acute myocardial infarction. Am J Cardiol (1996) 0.83
Left atrial compression by a mediastinal bronchogenic cyst presenting with paroxysmal atrial fibrillation. Thorax (1988) 0.82
Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. Nutr Metab Cardiovasc Dis (2010) 0.81
Relation between early mitral regurgitation and left ventricular thrombus formation after acute myocardial infarction: results of the GISSI-3 echo substudy. Heart (2002) 0.81
Renal ammoniagenesis in an early stage of metabolic acidosis in man. J Clin Invest (1982) 0.81
Predictors of nonfatal reinfarction in survivors of myocardial infarction after thrombolysis. Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2) Data Base. J Am Coll Cardiol (1994) 0.80
[Port malaria caused by Plasmodium falciparum a case report]. Infez Med (1996) 0.80
Severe reversible cardiac failure associated with methanol intoxication. Postgrad Med J (1987) 0.80
Thrombolysis in acute myocardial infarction. Chest (1991) 0.80
[Prinzmetal's angina initiated by interruption of exercise. 5 cases with normal coronary radiograms]. Arch Mal Coeur Vaiss (1979) 0.80
Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial. Diabetes Obes Metab (2009) 0.80
ISIS-4. GISSI-3 Investigators. Lancet (1995) 0.80
Evaluation of right ventricular function performed by 3D-echocardiography in scleroderma patients. Reumatismo (2015) 0.79
Ultrasound and radiology surrogate endpoints in pharmacological studies. Atherosclerosis (2012) 0.79
Nephrologists neglect administration of betablockers to dialysed diabetic patients. Nephrol Dial Transplant (1997) 0.79
Diltiazem improves left ventricular systolic function following acute myocardial infarction treated with streptokinase. The Calcium Antagonist in Reperfusion Study (CARES) Group. Am J Cardiol (1996) 0.78
Effects of metabolic alkalosis, metabolic acidosis and uraemia on whole-body intracellular pH in man. Clin Sci Mol Med (1977) 0.78
[Is a more efficient operative strategy feasible for the emergency management of the patient with acute chest pain?]. Ital Heart J Suppl (2000) 0.78
[Early functional evaluation and physical rehabilitation in patients with wide myocardial infarction (author's transl)]. G Ital Cardiol (1981) 0.78
Flecainide half-life prolongation in 2 patients with congestive heart failure and complex ventricular arrhythmias. Clin Pharmacokinet (1988) 0.78
Pericardial involvement in acute myocardial infarction in the post-thrombolytic era: clinical meaning and value. Clin Cardiol (1997) 0.78
Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutr Metab Cardiovasc Dis (2012) 0.78
Cardiac amyloidosis involving the conduction system and the aortocoronary neuroreceptors. Clinicopathologic correlates. Chest (1986) 0.78
Rheumatoid arthritis with monoclonal IgE rheumatoid factor. J Rheumatol (1993) 0.77
Absence of slowest oscillations in short term heart rate variability of post-myocardial infarction patients. GISSI-3 arrhythmias substudy. GISSI-3 Arrhythmias Substudy Investigators. Auton Neurosci (2001) 0.77
Administration of thrombolytic therapy to 17,944 patients with acute myocardial infarction: the GISSI-3 database. Am Heart J (1998) 0.77
Interferon retreatment in chronic hepatitis C: which patients to choose, and what schedule to use. Eur J Gastroenterol Hepatol (1999) 0.77
Thrombolytic therapy. From myocardial to cerebral infarction. The MAST-I Group. Multicentre Acute Stroke Trial. Ital J Neurol Sci (1996) 0.76
Measuring the occurrence of myocardial infarction. Eur Heart J (1999) 0.76
[Gamma-D-myeloma. Report of two cases (author's transl)]. Pathologica (1978) 0.76
Dynamic left ventricular outflow tract obstruction: an unusual mechanism mimicking anterior myocardial infarction with cardiogenic shock. Ital Heart J (2001) 0.76
[The gastric anatomico-functional aspects (parietal cell mass, stimulated acid secretion and gastrinemia) in pernicious anemia]. Ann Ital Med Int (1993) 0.76
Hypernatremia associated with severe rhabdomyolysis. Nephron (1989) 0.76
Urokinase thrombolytic therapy of pulmonary embolism in neurosurgically treated patients. Surg Neurol (1994) 0.76
Comparison between single morning and bedtime doses of 40 mg famotidine for the treatment of duodenal ulcer. Aliment Pharmacol Ther (1989) 0.76